At this time, a drug association consists of small molecule drugs improvements, such as non-steroidal anti-inflammatory drugs (NSAIDs), (disease-modifying antirheumatic drugs, and drugs curative biomacromolecule, such as tumor necrosis inhibitor factor-alpha, B-block inhibitor, inhibitors of cytokine receptors, the purpose of the nuclear aspects of biological preparation of receptor activator of kappa B ligand (RANKL) and purpose variable granulocyte-colony-stimulating macrophage, etc.
There appear advanced targeting treatment of RA, especially in the last 30 years. To know about cytokine visit https://www.bosterbio.com/services/multiplex-cytokine-assay-service
Although there is no cure for RA patients, early identification, early intervention, and direct therapy can help control the disease more efficiently and improve patient quality of life.
Rheumatoid arthritis (RA) is a chronic autoimmune disorder, whose main clinical indication is synovitis, cartilage injury, and trauma symmetrical joints. RA often occurs in small joints such as legs and arms, which can also affect other systems outside the joint, and even lead to joint deformity and loss of function.
The incidence of rheumatoid arthritis is 5% – 10%, which can be regionally differentiated. Girls are more prone to suffer from rheumatoid arthritis than men, and functional disability of patients with RA will reduce their ability to work and engagement, increase the cost of their treatment, further exacerbating the burden on society.
Joint injuries and more severe symptoms of RA are carried by immune complexes formed by a mixture of anti-citrullinated autoprotein antibodies produced by patients with RA and citrullinated autoprotein antigens in vivo, and then, collectively with rheumatoid factor, the high number of supplements is activated, disturbing abnormal immune reactions.